Department of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Department of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Antimicrob Agents Chemother. 2020 Apr 21;64(5). doi: 10.1128/AAC.01955-19.
Cefiderocol inhibited 97.5% of 478 Gram-negative isolates from cancer patients at ≤4 mg/liter. It had potent activity against extended-spectrum β-lactamase-positive , carbapenem-resistant (CRE), and nonfermenting Gram-negative bacilli, including , , and species isolates. Amikacin, ceftazidime-avibactam, and meropenem had appreciable activity against non-CRE No comparators were active against multidrug-resistant isolates. Only trimethoprim-sulfamethoxazole had appreciable activity against isolates. Overall, cefiderocol was associated with the lowest level of resistance.
头孢地尔在 ≤4 毫克/升时抑制了 478 株来自癌症患者的革兰氏阴性菌的 97.5%。它对产超广谱β-内酰胺酶阳性、碳青霉烯类耐药（CRE）和非发酵革兰氏阴性杆菌具有强大的活性，包括肠杆菌科、铜绿假单胞菌和不动杆菌属的分离株。阿米卡星、头孢他啶-阿维巴坦和美罗培南对非 CRE 的分离株具有相当的活性。没有比较药物对多药耐药的分离株具有活性。只有复方磺胺甲噁唑对分离株具有相当的活性。总的来说，头孢地尔的耐药率最低。
